Peptide YY (3-36)
Also known as: AC162352, Peptide YY (3-36), Peptide YY fragment 3-36, PYY 3-36, PYY(3-36), PYY3-36
Source Peptide YY (3-36) at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Peptide YY (3-36) (PYY3-36) is a 36‑amino‑acid gut hormone fragment that acts as a selective agonist of the Y2 neuropeptide Y receptor. It is released post‑prandially from L‑cells in the distal intestine and signals to the hypothalamus to reduce food intake. Research is exploring its potential as an investigational anti‑obesity agent, either alone or in combination with GLP‑1 agonists, and as a modulator of reward pathways linked to drug‑seeking behavior.
Mechanism of Action
PYY3-36 binds with high affinity to Y2 receptors located on NPY‑producing neurons in the arcuate nucleus of the hypothalamus. Activation of Y2 receptors inhibits NPY release, a potent orexigenic signal, thereby decreasing appetite and promoting satiety. Peripheral Y2 activation also slows gastric emptying and reduces gastrointestinal secretions, contributing to the overall anorectic effect. The peptide can cross the blood‑brain barrier, allowing central and peripheral actions to cooperate in energy balance regulation.
What the Research Shows
A 2024 review described the neural circuits through which PYY3-36, alone or combined with GLP‑1 agonists, suppresses food intake, drug‑seeking and anxiety‑related behaviors, highlighting its potential for synergistic therapy. Earlier reviews (2022) placed PYY3-36 among key gut hormones that integrate peripheral metabolic signals with central neurotransmitters to control energy homeostasis. Human and animal studies reported that bariatric surgery raises basal and meal‑stimulated PYY levels, correlating with post‑operative appetite suppression. Basic research showed that PYY3-36 is a specific Y2 agonist, whereas the full‑length PYY(1‑36) activates multiple Y receptors and can increase appetite. No large‑scale clinical efficacy trials were identified; evidence remains largely pre‑clinical and observational.
Reported Benefits
Preclinical data indicate that PYY3-36 reduces appetite, promotes weight loss, and may attenuate reward‑driven drug seeking when administered alone or with GLP‑1 agonists. Observational studies after bariatric procedures suggest that elevated endogenous PYY3-36 contributes to the sustained reduction in food intake seen in patients. Its selective Y2 receptor activation offers a mechanistic advantage by specifically inhibiting orexigenic NPY signaling without stimulating other Y receptors that could increase appetite.
Limitations of the Evidence
The therapeutic potential of PYY3-36 is supported mainly by animal models and short‑term human observations; no randomized controlled trials have confirmed efficacy or optimal dosing. Human data on endogenous PYY changes after surgery are limited and sometimes inconsistent. Mood‑related effects are unclear, with some concerns about anxiety or depression modulation. Consequently, the peptide remains investigational, and its translation to approved medication is uncertain.
Safety Considerations
PYY3-36 influences gastrointestinal motility, reducing gastric emptying and pancreatic secretion, which could cause nausea, abdominal discomfort, or altered nutrient absorption. The peptide has been reported to raise systolic and diastolic blood pressure, suggesting a need for cardiovascular monitoring. As a Y2 agonist, it may also affect blood pressure regulation and heart rate. No serious adverse events were detailed in the cited literature, but safety data are limited to preclinical and short‑term human observations.
How It Is Administered
Investigational formulations of PYY3-36 have been studied via intravenous, subcutaneous, nasal and oral routes. The peptide is typically delivered as a synthetic analogue or recombinant fragment. Dosing regimens, frequency, and formulation specifics have not been established in approved therapies and remain subject to ongoing research.
Routes of Administration
Goals & Uses
- Post-bariatric surgery gut hormone modulationMetabolic / SurgicalLow
- Type 2 diabetes / glycemic controlMetabolic / EndocrineLow
- Appetite suppression / Reduction of food intakeMetabolic / ObesityModerate
- Appetite suppressionMetabolicModerate
- Obesity treatmentMetabolicModerate
- Weight loss in obesityMetabolic / ObesityModerate
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Severe gastrointestinal dysmotilityGastrointestinalModerate
- severe gastrointestinal obstructionGastrointestinalHigh
- Eating disorders (anorexia nervosa)Psychiatric / NutritionalHigh
Adverse Effects
- Abdominal discomfortGastrointestinalCommon
- Injection site reactionsLocalUncommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- Dizziness / lightheadednessNeurologicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalUncommonForceful expulsion of stomach contents
- Nasal irritation / epistaxisLocal / NasalUncommon
Drug Interactions
- Other Y‑receptor agonistsHigh
- Oxyntomodulin / GLP-1/glucagon dual agonistsLow
- GLP‑1 receptor agonistsModerate
- GLP-1 receptor agonists (e.g., liraglutide, semaglutide)Moderate
- Opioid analgesicsModerate
Population Constraints
- Pediatric patientsAgeRelative
- Breastfeeding womenReproductiveRelative
- Children (<12 y)PediatricRelative
- Elderly (>75 y)AgeRelative
- Patients with renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionInvestigationalClinical research use only.
- United StatesInvestigationalPhase 2 trials for obesity.
- United KingdomInvestigationalNot licensed.
Not approved for any indication; used only in clinical trials and experimental settings.
Evidence & Sources
- Journal ArticleModerateDumiaty Y, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateLustig RH, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateBallantyne GH2006-01-01T00:00:00.000000Z
- Journal ArticleModerateBaynes KC, Dhillo WS, Bloom SR2006-01-01T00:00:00.000000Z
- Journal ArticleModerateSt-Pierre DH, Broglio F2010-01-01T00:00:00.000000Z
- Journal ArticleModerateBallantyne GH2006-01-01T00:00:00.000000Z
Frequently Asked Questions
How does PYY3-36 differ from the full‑length peptide PYY(1‑36)?
PYY(1‑36) binds to all four Y receptors (Y1, Y2, Y4, Y5) and can stimulate appetite via Y1 and Y5. In contrast, PYY3‑36 lacks the N‑terminal dipeptide and acts as a selective Y2 receptor agonist, which inhibits NPY release and produces an anorectic effect.
Can PYY3-36 be used to treat obesity today?
No. PYY3‑36 is currently classified as an investigational compound. While preclinical studies show appetite‑suppressing activity, there are no approved pharmaceutical products containing PYY3‑36 for obesity treatment.
What routes of administration have been explored for PYY3-36?
Research has examined intravenous, subcutaneous, nasal and oral delivery of synthetic PYY3‑36. Each route aims to achieve sufficient systemic exposure, but optimal delivery methods and dosing schedules have not been finalized.
Are there any known side effects of PYY3-36?
Reported physiological effects include slowed gastric emptying, reduced pancreatic secretion, and modest increases in blood pressure. Potential gastrointestinal discomfort and nausea are plausible, but comprehensive safety data from human trials are lacking.
Could PYY3-36 help with substance‑use disorders?
Preclinical work suggests that Y2‑mediated signaling by PYY3‑36 can dampen reward pathways linked to drug seeking. However, evidence is limited to animal studies, and clinical relevance remains unproven.
What is Peptide YY (3-36)?
Peptide YY (3-36) (PYY3-36) is a 36‑amino‑acid gut hormone fragment that acts as a selective agonist of the Y2 neuropeptide Y receptor. It is released post‑prandially from L‑cells in the distal intestine and signals to the hypothalamus to reduce food intake. Research is exploring its potential as an investigational anti‑obesity agent, either alone or in combination with GLP‑1 agonists, and as a modulator of reward pathways linked to drug‑seeking behavior.
What is Peptide YY (3-36) used for?
Peptide YY (3-36) is educationally associated with: Post-bariatric surgery gut hormone modulation, Type 2 diabetes / glycemic control, Appetite suppression / Reduction of food intake, Appetite suppression, Obesity treatment, Weight loss in obesity. Educational only — not medical advice.
How is Peptide YY (3-36) administered?
Recorded routes of administration: Intravenous, Nasal, Oral, Subcutaneous.
What are the potential side effects of Peptide YY (3-36)?
Reported adverse effects include: Abdominal discomfort, Injection site reactions, Headache, Dizziness / lightheadedness, Nausea, Vomiting, Nasal irritation / epistaxis. This list is not exhaustive — consult a qualified clinician.
Who should avoid Peptide YY (3-36)?
Recorded contraindications: Pregnancy, Severe gastrointestinal dysmotility, severe gastrointestinal obstruction, Eating disorders (anorexia nervosa). Consult a qualified clinician before use.